Pipeline-in-a-drug, page-139

First 139 Last

Share
Profile

Follow
Anydaynow

2,108 Posts.

551

05/06/24

06:32

Post #: 74166190
Share

Originally posted by giarc63: ↑

For Acadia to develop trofinetide for an indication just to preclude Neuren from developing NNZ2591 for the same indication is absurd.

The cost alone for Acadia to do that would be phenominal. I am not saying that Acadia does not have the right to progress trofinetide in any indication that it wishes to, but the likelihood of trofinetide to pass all the regulatory requirements is far less than the likelihood that the "superior drug" NNZ2591 would.

The sheer cost of Acadia doing this would drive them out of business.

Acadia is much better suited to progress NNZ2591 for Retts and Fragile-X and I have been waiting for that announcement to drop since the last agreement was signed with Neuren. John keeps saying that decision is totally up to Acadia. I believe also that John does not believe that Acadia would promote trofinetide in any undisclosed indication just to preclude Neuren from doing ii with NNZ2591. The cost alone of doing that should stop Acadia in its tracks.

Once again - the relationship between Acadia and Neuren has been convivial to this date and there is no reason to belive that it will not continue to be so.

The recent back track in the share price for Acadia can be attributed more to its failure with another drug and not to the preformance of Daybue/trofinetide.

Acadia Pharmaceuticals (NASDAQ:ACAD) faced a sharp decline this year after deciding not to proceed with further trials for pimavanserin, a drug aimed at treating schizophrenia, and now its outlook looks bleak or at least unfavorable.

Although the Daybue sales came in the lower ebb of the expected sales - Daybue/Trofinetide continues to serve its purpose for Neuren.

The future for Neuren definitely lies with NNZ2591 and I see no reason for concern as to the ability of NNZ2591 to treat multiple neurological indications. That is the scientific aim for this drug.

I also cannot see that Acadia would ever target an indication just to preclude Neuren from doing so, it cuts against the grain that they would ever consider doing that, let alone be able to afford to do so - in reality. That would be absurd.

Expand

I agree Giarc, just when NEU is seeing blue sky on it’s horizon with nary a cloud in sight HC posters are seeing smoke and mirrors.
FWIW I wouldn’t be surprised to see a takeover of both ACAD and NEU by a much much bigger BP, it would simplify the whole process and give an immediate revenue return in Trof without the need to pay royalties to NEU. IMHO NEU is worth at least x5 the price of ACAD.

NEU Price at posting: $19.02 Sentiment: Buy Disclosure: Held
18 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

First 139 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.31		Change 0.770(6.14%)		Mkt cap ! $1.650B

Open	High	Low	Value	Volume
$12.96	$14.00	$12.91	$19.76M	1.453M

Buyers (Bids)

No.	Vol.	Price($)
1	3000	$13.30

Sellers (Offers)

Price($)	Vol.	No.
$13.33	3716	1

View Market Depth

No.	Vol.	Price($)
1	3000	13.300
2	10200	13.200
1	2500	13.190
2	1750	13.180
1	50	13.170

Price($)	Vol.	No.
13.330	3716	1
13.370	3716	1
13.390	600	1
13.400	3783	2
13.430	3716	1

Last trade - 16.10pm 26/06/2025 (20 minute delay)

NEU (ASX) Chart

Pipeline-in-a-drug, page-139

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pipeline-in-a-drug, page-139

Top Stories

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News